Immunomedics Reports Durable Responses in Patients With Advanced Solid Cancers After Therapy With Sacituzumab Govitecan
October 19, 2015 at 14:37 PM EDT
Immunomedics, Inc., (Nasdaq: IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug ...